Investigators are searching for non-invasive biomarkers of rejection and earlier stage graft injury in children and adults who have received kidney transplants.
Heterozygous deletions at the chromosome 22q11.2 locus contribute to kidney problems in individuals with DiGeorge syndrome or congenital urogenital conditions.
The company said it will use the funds to commercialize its proteomic PromarkerD kidney disease test and launch an analytical testing service business.
With data from the CanPREDDICT study, the partners will develop a test to predict the rate of disease progression in patients with chronic kidney disease.
